

# EHA2026 Congress

June 11–14, 2026  
Stockholm, Sweden



## TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD.

Thank you to the funders of the GvHD Hub. All content is developed independently by SES in collaboration with an expert steering committee. Funders are allowed no influence. A full list of our supporters can be found at: [GvHDHub.com](https://GvHDHub.com).

# EHA2026: Top abstracts in GvHD

June 11–14, 2026

## Oral presentations: Thursday, June 11

Abstract	Title	Presenter	Time (CEST)
<b>S266</b> <a href="#">View</a>	ABC: An entirely calcineurin and m-TOR inhibitor-free short duration GvHD prevention regimen	A Samer Al-Homsi	17:00–17:15

## Oral presentations: Saturday, June 13

Abstract	Title	Presenter	Time (CEST)
<b>LB5009</b> <a href="#">View</a>	GvHD prophylaxis including ATG remains standard of care for HLA-compatible unrelated donor hematopoietic cell transplantation: Results from a large randomized controlled trial comparing ATG and PTCy	Johannes Schetelig	18:15–18:30

## Posters

Abstract	Title	Presenter	Date and time (CEST)
<b>PF1125</b> <a href="#">View</a>	The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory cGvHD	Yibo Wu	Friday, June 12, from 18:45
<b>PF1131</b> <a href="#">View</a>	Immunosuppressive strategy using low-dose ATG combined with anti-CD25 antibody for GvHD prophylaxis in haploidentical hematopoietic stem cell transplantation	Xiaosheng Fang	Friday, June 12, from 18:45
<b>PF1137</b> <a href="#">View</a>	The combination of ruxolitinib and extracorporeal photopheresis is a highly effective second line treatment for chronic graft-versus-host disease	Andrea Varkonyi	Friday, June 12, from 18:45
<b>PF1140</b> <a href="#">View</a>	Exploration of a novel aGvHD prophylaxis regimen based on gecacitinib in the peritransplant period of patients with myelofibrosis: A pilot open-label study	Na Xu	Friday, June 12, from 18:45
<b>PF1151</b> <a href="#">View</a>	Assessments of bone health among patients with chronic graft-versus-host disease receiving axatilimab in the AGAVE-201 trial	Amandeep Salhotra	Friday, June 12, from 18:45
<b>PF1179</b> <a href="#">View</a>	Association between serum biomarkers and acute graft-versus-host disease	Heng Liu	Friday, June 12, from 18:45
<b>PS2226</b> <a href="#">View</a>	Real-world use of post-transplant cyclophosphamide for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation: A survey from the CTIWP of EBMT	Shlomo Elias	Saturday, June 13, from 18:45
<b>PS2231</b> <a href="#">View</a>	Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease	Lipeng Liu	Saturday, June 13, from 18:45

**Posters (continued)**

<b>Abstract</b>	<b>Title</b>	<b>Presenter</b>	<b>Date and time (CEST)</b>
<b>PS2243</b> <a href="#">View</a>	Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Updated safety analysis of a randomized phase 2 study	Robert Zeiser	Saturday, June 13, from 18:45
<b>PS2244</b> <a href="#">View</a>	Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease	Yibo Wu	Saturday, June 13, from 18:45
<b>PS2264</b> <a href="#">View</a>	Clinical outcomes and safety of extracorporeal photopheresis alone or combined with ruxolitinib in chronic graft-versus-host disease	Christian Koch	Saturday, June 13, from 18:45
<b>PS2275</b> <a href="#">View</a>	Umbilical cord-derived mesenchymal stem cells: Elevating early efficacy in gastrointestinal acute graft-versus-host disease	Fang Zhou	Saturday, June 13, from 18:45
<b>PS2415</b> <a href="#">View</a>	Torque teno virus: An emerging biomarker associated with adverse prognosis and the risk of graft-versus-host disease in patients undergoing allo-HSCT	Xiujuan Ma	Saturday, June 13, from 18:45



**#EHA2026**

Follow us on X to keep up to date  
with the latest from the congress

**@GvHD\_Hub**



Brought to you by

